Norges Bank
RXRX icon

Norges Bank’s Recursion Pharmaceuticals RXRX Stock Holding History

Norges Bank’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.1M Buy
+6,833,534
New +$22.8M ﹤0.01% 1182
2026
Q1 		– Sell
-5,739,064
Closed -$23.5M – 1133
2025
Q4 		$23.5M Buy
+5,739,064
New +$28.4M ﹤0.01% 1207
2025
Q3 		– Sell
-3,169,938
Closed -$16M – 1257
2025
Q2 		$16M Sell
3,169,938
-242,065
-7% -$1.19M ﹤0.01% 1219
2025
Q1 		$18M Sell
3,412,003
-53,872
-2% -$393K ﹤0.01% 1213
2024
Q4 		$23.4M Sell
3,465,875
-106,681
-3% -$717K ﹤0.01% 1207
2024
Q3 		$23.5M Buy
3,572,556
+1,625,261
+83% +$11.7M ﹤0.01% 1194
2024
Q2 		$14.6M Sell
1,947,295
-1,225,247
-39% -$10.7M ﹤0.01% 1293
2024
Q1 		$31.6M Sell
3,172,542
-359,422
-10% -$4M 0.01% 1123
2023
Q4 		$34.8M Buy
3,531,964
+105,708
+3% +$754K 0.01% 1072
2023
Q3 		$26.2M Buy
3,426,256
+559,038
+19% +$5.58M 0.01% 1118
2023
Q2 		$21.4M Sell
2,867,218
-1,358,868
-32% -$9.51M ﹤0.01% 1227
2023
Q1 		$28.2M Sell
4,226,086
-145,227
-3% -$1.15M 0.01% 1107
2022
Q4 		$33.7M Hold
4,371,313
– – 0.01% 1002
2022
Q3 		$46.5M Buy
4,371,313
+116,006
+3% +$1.17M 0.01% 794
2022
Q2 		$34.6M Buy
4,255,307
+2,858,032
+205% +$19.1M 0.01% 960
2022
Q1 		$10M Buy
1,397,275
+1
+0% +$11 ﹤0.01% 1700
2021
Q4 		$23.9M Buy
1,397,274
+897,274
+179% +$16.9M ﹤0.01% 1379
2021
Q3 		$11.5M Hold
500,000
– – ﹤0.01% 1720
2021
Q2 		$18.3M Buy
+500,000
New +$14.8M ﹤0.01% 1581

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Norges Bank's RXRX Position: Q2 2026 in Review

Norges Bank opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 6,833,534 shares worth $25.1M. The stake represents ﹤0.01% of the portfolio and ranks #1182 among its holdings. This is a return to the name: Norges Bank previously reported a position in RXRX as recently as Q4 2025.

Norges Bank first reported a position in RXRX in Q2 2021 and has held it in 19 quarters since. The position peaked at $46.5M in Q3 2022. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Norges Bank held 6,833,534 shares of Recursion Pharmaceuticals worth $25.1M as of Q2 2026.
  • Recursion Pharmaceuticals was a new Norges Bank position in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Norges Bank's portfolio in Q2 2026, its #1182 holding.
  • Norges Bank first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 19 quarters since.
  • Norges Bank's Recursion Pharmaceuticals position peaked at $46.5M in Q3 2022.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Norges Bank's 13F filing for Q2 2026, filed 12 Aug 2026.